No Data
No Data
LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $27
Promising Outlook for Olema Pharmaceuticals: Buy Rating Affirmed Amid Strategic Positioning in ER+ Breast Cancer Treatment
After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA)
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)